Inclusion Criteria

Inclusion Criteria

- Subject must be >/= 18 years of age.

- Subject must have a histologically or cytologically confirmed non-hematologic
malignancy.

- Eastern cooperative Oncology Group (ECOG) Performance Score of 0 to 2.

- Subject must have adequate bone marrow, renal and hepatic function.

- Subject must have Partial Thromboplastin Time (PTT) (ULN) and International Normalized Ratio (INR)
- Subject must be capable of understanding and complying with parameters as outlined in
the protocol and able to sign the informed consent.

Exclusion Criteria

- Subject has received previous administration of a radiolabeled research substance
within 12 months prior to Study Day 1 or exposure to significant radiation (e.g.,
barium meal, etc.) within the past 3 months or within a period defined by 5
half-lives, whichever is shorter, prior to Study Day 1.

- Subject has received anti-cancer therapy including investigational agents, cytotoxic
chemotherapy, radiation, hormonal or biologic therapy within 21 days or within a
period defined by 5 half-lives, whichever is shorter, prior to Study Day 1.

- Subject is currently using a known inhibitor (e.g., ketoconazole) or inducer (e.g.,
rifampin) of cytochrome P450 3A (CYP3A) within 1 month prior to Study Day 1.

- Subject has not recovered to less than or equal to grade 1 clinically significant
adverse effects/toxicities of the previous therapy.

- Subject has undergone major surgery within 21 days of Study Day 1.

- The subject has brain or meningeal metastases.

- The subject has non-small cell lung cancer (NSCLC) with a predominant squamous cell
histology.

- Subject is receiving therapeutic anticoagulation therapy.

- Subject has a history of/or currently exhibits clinically significant events of
bleeding (e.g., hemoptysis).

- Subject has proteinuria Common Terminology Criteria (CTC) Grade > 2 at baseline.

- Subject currently exhibits symptomatic or persistent, uncontrolled hypertension.

- Subject has a history of myocardial infarction within 6 months.

- Subject has known autoimmune disease with renal involvement.

- Subject is receiving combination anti-retroviral therapy for human immunodeficiency
virus (HIV).

- Clinically significant uncontrolled conditions/medical symptoms.

- Subject has a documented left ventricular (LV) ejection fraction < 50%.

- Subject has previously received linifanib.